These effects weaken immunosuppressive responses, enhance the activity of PD-1 and PD-L1 inhibitors, and further promote robust immune responses, highlighting the potential of HAIC-based combination therapies in advanced iCCA. This evidence concerns the gene CD274 and infantile convulsions and choreoathetosis.